456 related articles for article (PubMed ID: 26068066)
21. Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases.
Iagaru A; Young P; Mittra E; Dick DW; Herfkens R; Gambhir SS
Clin Nucl Med; 2013 Jul; 38(7):e290-6. PubMed ID: 23455520
[TBL] [Abstract][Full Text] [Related]
22. ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.
Dammacco F; Rubini G; Ferrari C; Vacca A; Racanelli V
Clin Exp Med; 2015 Feb; 15(1):1-18. PubMed ID: 25218739
[TBL] [Abstract][Full Text] [Related]
23. [18F-FDG PET/CT and 99mTc-MIBI scintigraphy in evaluation of patients with multiple myeloma and monoclonal gammopathy of unknown significance: comparison of methods].
Myslivecek M; Bacovský J; Scudla V; Koranda P; Minarík J; Buriánková E; Formánek R; Zapletalová J
Klin Onkol; 2010; 23(5):325-31. PubMed ID: 21061682
[TBL] [Abstract][Full Text] [Related]
24. Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancy.
Lin FI; Rao JE; Mittra ES; Nallapareddy K; Chengapa A; Dick DW; Gambhir SS; Iagaru A
Eur J Nucl Med Mol Imaging; 2012 Feb; 39(2):262-70. PubMed ID: 22065013
[TBL] [Abstract][Full Text] [Related]
25. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study.
Fonti R; Pace L; Cerchione C; Catalano L; Salvatore B; De Luca S; Pane F; Salvatore M; Del Vecchio S
Clin Nucl Med; 2015 Apr; 40(4):303-8. PubMed ID: 25608167
[TBL] [Abstract][Full Text] [Related]
26. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe).
Nanni C; Versari A; Chauvie S; Bertone E; Bianchi A; Rensi M; Bellò M; Gallamini A; Patriarca F; Gay F; Gamberi B; Ghedini P; Cavo M; Fanti S; Zamagni E
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):712-719. PubMed ID: 29270787
[TBL] [Abstract][Full Text] [Related]
27. Incremental Value of Cocktail 18F-FDG and 18F-NaF PET/CT Over 18F-FDG PET/CT Alone for Characterization of Skeletal Metastases in Breast Cancer.
Roop MJ; Singh B; Singh H; Watts A; Kohli PS; Mittal BR; Singh G
Clin Nucl Med; 2017 May; 42(5):335-340. PubMed ID: 28263210
[TBL] [Abstract][Full Text] [Related]
28. Value of FDG PET in the assessment of patients with multiple myeloma.
Bredella MA; Steinbach L; Caputo G; Segall G; Hawkins R
AJR Am J Roentgenol; 2005 Apr; 184(4):1199-204. PubMed ID: 15788594
[TBL] [Abstract][Full Text] [Related]
29. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma.
Mosavi F; Johansson S; Sandberg DT; Turesson I; Sörensen J; Ahlström H
AJR Am J Roentgenol; 2012 Nov; 199(5):1114-20. PubMed ID: 23096187
[TBL] [Abstract][Full Text] [Related]
30. The value of FDG PET/CT in the initial staging and bone marrow involvement of patients with multiple myeloma.
Sager S; Ergül N; Ciftci H; Cetin G; Güner SI; Cermik TF
Skeletal Radiol; 2011 Jul; 40(7):843-7. PubMed ID: 21229354
[TBL] [Abstract][Full Text] [Related]
31. ¹⁸F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review.
van Lammeren-Venema D; Regelink JC; Riphagen II; Zweegman S; Hoekstra OS; Zijlstra JM
Cancer; 2012 Apr; 118(8):1971-81. PubMed ID: 21887677
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Tc-99m sestamibi and F-18 FDG-PET in the assessment of multiple myeloma.
Hung GU; Tsai CC; Tsai SC; Lin WY
Anticancer Res; 2005; 25(6C):4737-41. PubMed ID: 16334169
[TBL] [Abstract][Full Text] [Related]
33. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma.
Fonti R; Larobina M; Del Vecchio S; De Luca S; Fabbricini R; Catalano L; Pane F; Salvatore M; Pace L
J Nucl Med; 2012 Dec; 53(12):1829-35. PubMed ID: 23071351
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic utility of FDG PET in multiple myeloma.
Jadvar H; Conti PS
Skeletal Radiol; 2002 Dec; 31(12):690-4. PubMed ID: 12483429
[TBL] [Abstract][Full Text] [Related]
35. Bone involvement in patients with lymphoma: the role of FDG-PET/CT.
Schaefer NG; Strobel K; Taverna C; Hany TF
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):60-7. PubMed ID: 17021808
[TBL] [Abstract][Full Text] [Related]
36. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
Ak I; Sivrikoz MC; Entok E; Vardareli E
Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
[TBL] [Abstract][Full Text] [Related]
37. [The value of fluorodeoxyglucose positron emission tomography in multiple myeloma].
Adam Z; Bolcák K; Stanícek J; Pour L; Hájek R; Krejcí M; Prásek J; Neubauer J; Mareschova Y; Vorlícek J
Vnitr Lek; 2006 Mar; 52(3):207-14. PubMed ID: 16722151
[TBL] [Abstract][Full Text] [Related]
38. Characterizing and predicting pathologic spine fractures in myeloma patients with FDG PET/CT and MR imaging.
Mulligan M; Chirindel A; Karchevsky M
Cancer Invest; 2011 Jun; 29(5):370-6. PubMed ID: 21599514
[TBL] [Abstract][Full Text] [Related]
39. Early bone marrow metastasis detection: the additional value of FDG-PET/CT vs. CT imaging.
Evangelista L; Panunzio A; Polverosi R; Ferretti A; Chondrogiannis S; Pomerri F; Rubello D; Muzzio PC
Biomed Pharmacother; 2012 Sep; 66(6):448-53. PubMed ID: 22902054
[TBL] [Abstract][Full Text] [Related]
40. 11C-acetate PET/CT for metabolic characterization of multiple myeloma: a comparative study with 18F-FDG PET/CT.
Ho CL; Chen S; Leung YL; Cheng T; Wong KN; Cheung SK; Liang R; Chim CS
J Nucl Med; 2014 May; 55(5):749-52. PubMed ID: 24676754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]